Cytoreductive Surgery for Gynecologic Malignancies-New Standards of Care

Surgical Oncology Clinics of North America

Volumn 16, Issue 3, 2007, Pages 667-682

  Suh Burgmann, Elizabeth ^a   Powell, C Bethan ^b  

^a KAISER PERMANENTE MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; PACLITAXEL;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; ENDOMETRIUM CANCER; GYNECOLOGIC CANCER; HUMAN; OVARY CANCER; PROGNOSIS; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ENDOMETRIAL NEOPLASMS; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; INFUSIONS, PARENTERAL; NEOADJUVANT THERAPY; OVARIAN NEOPLASMS;

EID: 34347217886     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2007.04.017     Document Type: Review

References (84)

1. National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch. Surveillance, Epidemiology, and End Results (SEER) Program, Public-Use Data (1973-2004). Available at: http://www.cancer.gov. Accessed May 24, 2007.
2. Chan J.K., Cheung M.K., Husain A., et al. Patterns and progress in ovarian cancer over 14 years. Obstet Gynecol 108 (2006) 521-528
3. Armstrong D.K., Bundy B., Wenzel L., et al. Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354 (2006) 34-43
4. Magtibay P.M., Adams P.B., Silverman M.B., et al. Splenectomy as part of cytoreductive surgery in ovarian cancer. Gynecol Oncol 102 (2006) 369-374
5. Bloss J.D., Liao S.Y., Buller R.E., et al. Extraovarian peritoneal serous papillary carcinoma: a case-control retrospective comparison to papillary adenocarcinoma of the ovary. Gynecol Oncol 50 3 (1993) 347-351
6. Bloss J.D., Brady M.F., Liao S.Y., et al. Gynecologic Oncology Group Study. Extraovarian peritoneal serous papillary carcinoma: a phase II trial ofcisplatin and cyclophosphamide with comparison to a cohort with papillary serous ovarian carcinoma-a Gynecologic Oncology Group Study. Gynecol Oncol 89 1 (2003) 148-154
7. Ayhan A., Taskiran C., Yigit-Celik N., et al. Long-term survival after paclitaxel plus platinum-based combination chemotherapy for extraovarian peritoneal serous papillary carcinoma: is it different from that for ovarian serous papillary cancer?. Int J Gynecol Cancer 16 2 (2006) 484-489
8. Dubernard G., Morice P., Rey A., et al. Prognosis of stage III or IV primary peritoneal serous papillary carcinoma. Eur J Surg Oncol 30 9 (2004) 976-981
9. Killackey M.A., and Davis A.R. Papillary serous carcinoma of the peritoneal surface: matched-case comparison with papillary serous ovarian carcinoma. Gynecol Oncol 51 2 (1993) 171-174
10. Koutselini H.A., Lazaris A.C., Thomopoulou G., et al. Papillary serous carcinoma of peritoneum: case study and review of the literature on the differential diagnosis of malignant peritoneal tumors. Adv Clin Path 5 (2001) 99-104
11. Munnell E.W. The changing prognosis and treatment in cancer of the ovary. Am J Obstet Gynecol 100 (1969) 790-805
12. Griffiths C.T. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 42 (1975) 101-104
13. Hoskins W.J., McGuire W.P., Brady M.F., et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 170 (1994) 974-979
14. Vogl S.E., Pagano M., Kaplan B.H., et al. Cisplatin based combination chemotherapy for advanced ovarian cancer: high overall response rate with curative potnetial only in women with small tumor burden. Cancer 51 (1983) 2024-2030
15. Delgado G., Oram D.H., and Petrilli E.S. Stage III epithelial ovarian cancer: the role of maximal surgical reduction. Gynecol Oncol 18 (1984) 293-298
16. Conte P.F., Sertoli M.R., Bruzzone M., et al. Cisplatin, methotrexate and 5-fluorouracil combination chemotherapy for advanced ovarian cancer. Gynecol Oncol 5 (1985) 290-297
17. Posada Jr. J.G., Marantz A.B., Yeung K.Y., et al. The cyclophosphamide, hexamethylmelamine, 5-fluorouracil (CHF) regimen in the treatment of advanced and recurrent ovarian cancer. Gynecol Oncol 20 (1985) 23-31
18. Neijt J.P., ten Bokkel Huinink W.W., van der Burg M.E., et al. Long-term survival in ovarian cancer: mature data from The Netherlands Joint Study Group for Ovarian Cancer. Eur J Cancer 27 (1991) 1367-1372
19. Hainsworth J.D., Grosh W.W., Burnett L.S., et al. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherpay of brief duration. Ann Intern Med 108 (1988) 165-170
20. Piver M.S., Lele S.B., Marchetti D.L., et al. Surgical documented response to intraperitoneal cisplatin, cytarabine, and bleomycin after intravenous cisplatin-based chemotherapy in advanced ovarian adenocarcinoma. J Clin Oncol 6 (1988) 1679-1684
21. Sutton G.P., Stehman F.B., Einhorn L.H., et al. Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma. J Clin Oncol 7 (1989) 223-229
22. Bertelsen K. Tumor reduction surgery and long-term survival in advanced ovarian cancer: a DACOVA study. Gynecol Oncol 38 (1990) 203-209
23. Gershenson D.M., Wharton J.T., and Copeland L.J. Treatment of advanced epithelial ovarian cancer with cisplatin and cyclophosphamide. Gynecol Oncol 32 (1989) 336-351
24. Chi D.S., Eisenhauer E.L., Lang J., et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?. Gynecol Oncol 103 2 (2006) 559-564 [Epub 2006 May 22]
25. Allen D.G., Heintz A., and Touw F.W. A meta-analysis of residual disease and survival in stage III and IV carcinoma of the ovary. Eur J Gynaecol Oncol 16 (1995) 349-356
26. Hunter R.W., Alexander N.D., and Soutter W.R. Meta-analysis of surgery in advance ovarian carcinoma: Is maximum cytoreductive surgery an independent determinant of prognosis?. Am J Obstet Gynecol 166 (1992) 504-511
27. Bristow R.E., Tomacruz R.S., Armstrong D.K., et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20 (2002) 1248-1259
28. Eisenkop S.M., Spirtos N.M., and Lin W.C. Splenectomy in the context of primary cytoreductive operations for advanced epithelial ovarian cancer. Gynecol Oncol 100 (2006) 344-348
29. Chi D.S., Franklin C.C., Levine D.A., et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol 94 (2004) 650-4
30. Chen L.M., Leuchter R.S., Lagasse L.D., et al. Splenectomy and surgical cytoreduction for ovarian cancer. Gynecol Oncol 77 (2000) 362-368
31. Scarabelli C., Campagnutta E., Zarelli A., et al. Splenectomy in cytoreductive surgery in ovarian cancer. Minerva Ginecol 45 (1993) 19-25
32. Aletti G.D., Dowdy S.C., Podratz K.C., et al. Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecol Oncol 100 (2006) 283-287
33. Eisenkop S.M., Nalick R., Wang H.J., et al. Peritoneal implant elimination during cytoreductive surgery of ovarian cancer: impact on survival. Gynecol Oncol 51 (1993) 224-229
34. Rose P.G. The cavitational ultrasonic surgical aspirator for cytoreduction in advanced ovarian cancer. Am J Obstet Gynecol 166 (1992) 843-846
35. Heintz A.P.M., Hacker N.F., Berek J.S., et al. Cytoreductive surgery in ovarian carcinoma: feasibility and morbidity. Obstet Gynecol 67 (1986) 783-788
36. Piver M.S., and Baker T. The potential for optimal (<2 cm) cytoreductive surgery in advanced ovarian carcinoma at a tertiary medical center: a prospective study. Gynecol Oncol 24 (1986) 1-8
37. Eisenkop S.M., Friedman R.L., and Wang H.J. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol 69 (1998) 103-108
38. Liu P.C., Benjamin I., Morgan M.A., et al. Effect of surgical debulking on survival in stage IV ovarian cancer. Gynecol Oncol 64 (1997) 4-8
39. Guidozzi F., and Ball J.H.S. Extensive primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol 53 (1994) 326-330
40. Michel G., De Iaco P., Castaigne D., et al. Extensive cytoreductive surgery in advanced ovarian carcinoma. Eur J Gynaecol Oncol 18 (1997) 9-15
41. Mourton S.M., Temple L.K., Abu-Rustum N.R., et al. Morbidity of rectosigmoid resection and primary anastomosis in patients undergoing primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol 99 (2005) 608-614
42. Obermair A., Hagenauer S., Tamandl D., et al. Safety and efficacy of low anterior en bloc resection as part of cytoreductive surgery for patients with ovarian cancer. Gynecol Oncol 83 (2001) 115-120
43. Bristow R.E., del Carmen M.G., Kaufman H.S., et al. Radical oophorectomy with primary stapled colorectal anastomosis for resection of locally advanced anastomosis for resection of locally advanced epithelial ovarian cancer. J Am Coll Surg 197 (2003) 565-774
44. Eisenkop S.M., Nalick R.H., and Teng N.N. Modified posterior exenteration for ovarian cancer. Obstet Gynecol 78 (1991) 879-885
45. Park J.Y., Seo S.S., Kang S., et al. The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns. Gynecol Oncol 103 (2006) 977-984
46. Tebes S.J., Cardosi R., and Hoffman M.S. Colorectal resection in patients with ovarian and primary peritoneal carcinoma. Am J Obstet Gynecol 195 (2006) 585-589
47. Earle C.C., Schrag D., Neville B.A., et al. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Instit 98 (2006) 172-180
48. Eisenkop S.M., Spirtos N.M., Montag T.W., et al. The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol Oncol 47 (1992) 203-209
49. Engelen M.J., Kos H.E., Pax H.B., et al. Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer 106 (2006) 589-598
50. Aletti GD, Dowdy SC, Gostout BS, et al. Aggressive surgical effort and improved survival in advanced stage ovarian cancer. Obstet Gynecol 2006;107:77-85.
51. Berek J.S., Hacker N.F., LaGasse L.D., et al. Second-look laparotomy in stage III epithelial ovarian cancer: clinical variables associated with disease status. Obstet Gynecol 64 (1984) 207-212
52. Redman J.F., Petroni G.R., Saigo P.E., et al. Prognostic factors in advanced ovarian carcinoma. J Clin Oncol 4 (1986) 515-523
53. Eisenhauer E.L., Abu-Rustum N.R., Sonoda Y., et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol 103 (2006) 1083-1090
54. Le T., Krepart G.V., Lotocki R.J., et al. Does debulking surgery improve survival in biologically aggressive ovarian carcinoma?. Gynecol Oncol 67 (1997) 208-214
55. Hacker N.F., Berek J.S., Lagasse L.D., et al. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 61 (1983) 413-420
56. Curtin J.P., Malik R., Venkatraman E.S., et al. Stage IV ovarian cancer: impact of surgical debulking. Gynecol Oncol 64 (1997) 9-12
57. Munkarah A.R., Hallum III A.V., Morris M., et al. Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer. Gynecol Oncol 64 (1997) 13-17
58. Gervais D.A., Arellano R.S., and Mueller P.R. Percutaneous radiofrequency ablation of ovarian cancer metastasis to the liver: indications, outcomes, and role in patient management. AJR Am J Roentgenol 180 (2006) 746-750
59. Mateo R., Singh G., Jabbour N., et al. Optimal cytoreduction after combined resection and radiofrequency ablation of hepatic metastases from recurrent malignant ovarian tumors. Gynecol Oncol 97 (2005) 266-270
60. Yoon S.S., Jarnagin W.R., Fong Y., et al. Resection of recurrent ovarian or fallopian tube carcinoma involving the liver. Gynecol Oncol 91 (2003) 383-388
61. Memarzadeh S., Holschneider C.H., Bristow R.E., et al. FIGO stage III and IV uterine papillary serous carcinoma: impact of residual disease on survival. Int J Gynecol Cancer 12 (2002) 454-458
62. Geisler J.P., Geisler H.E., Melton M.E., et al. What staging surgery should be performed on patients with uterine papillary serous carcinoma?. Gynecol Oncol 74 (1999) 465-467
63. Bristow R.E., Duska L.R., and Montz F.J. The role of cytoreductive surgery in the management of stage IV uterine papillary serous carcinoma. Gynecol Oncol 81 (2001) 92-99
64. Lambrou N.C., Gomez-Marin O., Mirhashemi R., et al. Optimal surgical cytoreduction in patients with Stage III and Stage IV endometrial carcinoma: a study of morbidity and survival. Gynecol Oncol 93 (2004) 653-658
65. Chi D.S., Welshinger M., Venkatraman E.S., et al. The role of surgical cytoreduction in Stage IV endometrial carcinoma. Gynecol Oncol 67 (1997) 56-60
66. Alberts D.S., Liu P.Y., Hannigan E.V., et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335 (1996) 1950-1955
67. Markman M., Bundy B.N., Alberts D.S., et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19 (2001) 1001-1007
68. Shapiro F., Schneider J., Markman M., et al. High-intensity intravenous cyclophosphamide and cisplatin, interim surgical cytoreductive, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up. Gynecol Oncol 67 (1997) 39-45
69. Walker J.L., Armstrong D.K., Huang H.Q., et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 100 (2006) 27-32
70. Trimble E. NCI clinical announcement on intraperitoneal chemotherapy in ovarian cancer. Available at: http://ctep.cancer.gove/highlights/ovarian.html. Accessed January 6, 2006.
71. Ozols R.F., Bundy B.N., Greer B.E., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21 (2003) 3194-3200
72. van der Burg M.E., van Lent M., Buyse M., et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 332 (1995) 629-634
73. Bristow RE, Eisenhauer EL, Santillan A, et al. Delaying the primary surgical effort for advanced ovarian cancer. A systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecol Oncol 2007;104:480-90.
74. Rose P.G., Nerenstone S., Brady M.F., et al. Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 351 (2004) 2489-2497
75. Onda T., Yoshikawa H., Yasugi T., et al. Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection. Br J Cancer 92 (2005) 1026-1032
76. Berek J.S., Hacker N.F., LaGasse L.D., et al. Survival of patients following secondary cytoreductive surgery in ovarian cancer. Obstet Gynecol 61 (1983) 189-193
77. Morris M., Gershenson D.M., Wharton J.T., et al. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecol Oncol 34 (1989) 334-338
78. Janicke F., Holscher M., Kuhn W., et al. Radical surgical procedure improves survival time in patients with recurrent ovarian cancer. Cancer 70 (1992) 2129-2136
79. Gadducci A., Iacconi P., Cosio S., et al. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer. Gynecol Oncol 79 (2000) 344-349
80. Eisenkop S.M., Friedman R.L., and Wang H.J. Secondary cytoreduction for recurrent ovarian cancer. A prospective study. Cancer 76 (1995) 1606-1614
81. Zang R.Y., Zhang Z.Y., Li Z.T., et al. Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer. J Surg Oncol 75 (2000) 24-30
82. Chi D.S., McCaughty K., Diaz J.P., et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 106 (2006) 1933-1939
83. Nguyen H.N., Averette H.E., Hoskins W., et al. National Survey of Ovarian Carcinoma: V. The impact of physician's specialty on patients' survival. Cancer 72 (1993) 3663-3670
84. Elit L., Bondy S.J., Paszat, et al. Oucomes in surgery for ovarian cancer. Gynecol Oncol 887 (2002) 260-267